Nexavar

Patent board rules against Bayer in cancer drug case

An Indian board in Chennai has upheld a domestic pharmaceutical company's right to sell a generic version of Bayer AG's cancer drug Nexavar at much cheaper prices, but increased the royalty it should pay. Bayer has decided to challenge the decision. ...  

Cancer drug made cheaper, patients to benefit

Mumbai: The Indian Patent Office has given the Hyderabad-based Natco Pharma Limited the go-ahead in the form of a compulsory license to legally make and sell a low-cost generic version of German company Bayer's anti-cancer drug, Nexavar. The Controller of Patents PH Kurian, in a 62-page ruling, observed that with Nexavar priced at Rs 2,80,000 for a month's treatment, Bayer has not adequately worked the patent, adding that Nexavar was...  

Industry split over nod to Natco to sell Bayer's drug

New Delhi: India's decision to allow Natco Pharma to sell Bayer's patented cancer drug Nexavar has divided the pharmaceutical industry with domestic firms welcoming it while multinationals said 'arbitrarily' using of compulsory licenses will undermine innovation in the sector. Disappointed with the development, Bayer said it is evaluating options for its next step. "We are disappointed by the decision of the Patent Controller in India to grant a compulsory license...  

Rs 2.84-lakh cancer drug to cost Rs 8,880

New Delhi: Bringing huge relief to cancer and kidney patients in India, the government on Monday allowed Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder and German multinational Bayer Corporation under Section 84 of the Indian Patent Act. The order was issued by India Patents Office as a 'Compulsory Licence' under the Indian Patent Act, which...